CDT Equity Inc. Common Stock (CDT)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a margin of safety. CDT Equity is not yet that. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported a net loss of $4.6 million; in fiscal Q1 2026, ended 2026-03-31, a net loss of $4.1 million. For FY2025 it lost $39.2 million, and FY2024 $17.8 million. No revenue appears in any filed period. The FairStock metrics confirm the picture: Piotroski F-Score 1/9, Altman Z-Score -0.66, ROE -69.68%, ROCE -23.43%, and free cash flow of -$13.5 million, a -90.1% FCF yield against a $15 million market cap. The balance sheet has low reported leverage, D/E 0.01, which is a small mercy. The company describes three clinical-stage assets, including AZD1656 in Phase II, but with four employees and no sales, I see no evidence of a moat—only the hope that early science becomes valuable. The supplied profit growth figure is 23.01%, but that cannot offset the absolute losses. Valuation is difficult: P/E and P/B are shown as 0.00. At $0.45 on 2026-10-13, the market cap is $15 million, and FairStock Score is 13/100. The stock's 52-week range of $0.13 to $112.50 shows how violently expectations have swung. Growth in losses—from FY2023's $535,000 to FY2024 and FY2025's much larger deficits—is not the growth I want. Unless the pipeline produces cash or partnership value, the equity is a speculation, not a Graham-style bargain.

In plain English: CDT Equity is a very small healthcare company trying to develop and sell rights to experimental medicines. It has no reported revenue, has lost money for years, and its most recent quarterly loss was $4.6 million. At $0.45 a share, the price looks expensive compared with the business's current numbers because there are no sales or profits yet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer